( January 16, 2026, 3:48 PM EST) -- WASHINGTON, D.C. — The U.S. Supreme Court on Jan. 16 granted a bioequivalent pharmaceutical maker’s petition for a writ of certiorari, agreeing to consider its challenge to the Federal Circuit U.S. Court of Appeals’ finding that the petitioner’s “skinny label” generic version of a prescription cardiovascular medication constituted reverse infringement (Hikma Pharmaceuticals USA Inc., et al. v. Amarin Pharma, Inc., et al., No. 24-889, U.S. Sup.)....